MONTREAL, QUEBEC AND CAMBRIDGE, ENGLAND--(Marketwire - Aug. 27, 2007) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that its UK-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has achieved key performance milestones for its new MAbsorbent® ligands targeted at the purification of monoclonal antibodies ("MAbs") and recombinant antibody fragments ("Fabs"). The performance of ProMetic's new ligands against set targets was validated in collaboration with seven leading antibody producer companies in the United States and Europe.
